



First ROXUS® Prescriptions Fulfilled in the United States

06 October 2026

Highlights

- First patient-specific ROXUS® prescriptions received through Mavrox, Shed's men's health telehealth platform, have now been fulfilled in the United States.
- Mavrox provides the initial U.S. direct-to-consumer telehealth route for ROXUS, with Strive Pharmacy supporting prescription compounding and fulfilment.
- LTR Pharma will now focus on supporting its U.S. partners as prescribing and prescription activity builds.

LTR Pharma Limited (ASX: LTP) ("LTR Pharma" or "the Company") is pleased to announce that the first patient-specific ROXUS® prescriptions received through Mavrox, Shed's men's health telehealth platform, have now been fulfilled in the United States.

The milestone marks the commencement of ROXUS prescription activity through the telehealth and pharmacy arrangements established under LTR Pharma's agreements with Shed and Strive Pharmacy.

The first prescriptions follow completion of the operational work required to support ROXUS prescription fulfilment in the United States.

ROXUS is LTR Pharma's intranasal medication for erectile dysfunction support, compounded and dispensed in the United States by a licensed pharmacy under the patient-specific compounding provisions of Section 503A of the US Federal Food, Drug, and Cosmetic Act.

U.S. Prescription Fulfilment

Strive Pharmacy has established the operational systems required to receive, compound and fulfil valid patient-specific ROXUS prescriptions.

LTR Pharma Executive Chairman, Lee Rodne, said:

"Fulfilment of the first ROXUS prescriptions in the United States is an important milestone for LTR Pharma and our US partners.

With our first prescriptions now received through Mavrox, we have moved from implementation to serving patients under these arrangements. Our focus is now on supporting our partners as prescribing and prescription activity builds.

This milestone comes less than three months after we announced our agreement with Shed to establish a U.S. telehealth route to patients."



Next Steps

LTR Pharma will continue working with Shed and Strive Pharmacy to support ROXUS prescription fulfilment through Mavrox. The Company will provide further updates on US prescription activity as meaningful information becomes available.

ROXUS is a compounded medication prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, is not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA. Prescribers should use their independent clinical judgement when determining appropriateness for individual patients.

– ENDS –

This announcement has been authorised for release by the Board of LTR Pharma Limited.

Forward-looking statement

This announcement contains forward-looking statements, including in relation to ongoing US prescription activity and prescription fulfilment. These statements involve risks and assumptions beyond the Company's control, and actual results may differ materially. The Company does not undertake to update any forward-looking statement except as required by law.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, **SPONTAN®** and **ROXUS®**, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing **OROFLOW®**, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.



LTR Pharma

LTR Pharma Investor Centre

Stay informed with LTR Pharma's latest announcements and market updates by visiting our [Investor Centre](#) or scan the QR code.



For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com